IDRx
3 known investors
Find your way into IDRx
277 people in our graph share verified history with the IDRx team — schools, employers, funds. One of them is your warm intro.
Dan Lynchunlockedknows Tim Clackson · together at Xilio Therapeutics (overlapped)
×3knows the team · via University of Cambridge
knows the team · via University of Oxford
knows the team · via Xilio Therapeutics
×4knows the team · via Genentech
×2knows the team · via PanTher Therapeutics
IDRx discovers, develops and delivers medicines and vaccines focused on cancer, HIV, respiratory diseases, and infectious diseases. The company aims to positively impact the health of 2.5 billion people by the end of the decade.
Founders & leadership
TC
Tim ClacksoninA biotech executive whose leadership roles include President and CEO of Theseus Pharmaceuticals and President and Chief Technology Officer at Xilio Therapeutics. He has served on the boards of Elevation Oncology, Forma Therapeutics, MassBio, Kesmalea Therapeutics, and PanTher Therapeutics.
Investors · 3
Funding
SEC filings, press & company announcements$120M disclosed across 1 of 4 rounds · 2022–2024
- Undisclosed amountSeries BAug 2024Source ↗
- $120MraisedAug 2024 · 2 sourcesSource ↗
- Undisclosed amountSeries AAug 2022Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does IDRx do?
- IDRx discovers, develops and delivers medicines and vaccines focused on cancer, HIV, respiratory diseases, and infectious diseases. The company aims to positively impact the health of 2.5 billion people by the end of the decade.
- Who are IDRx's investors?
- IDRx's investors include Andreessen Horowitz, Nextech Invest, RA Capital.
- How much funding has IDRx raised?
- IDRx has disclosed $120M raised across 1 of its 4 known rounds.